A Study to Assess the Safety and Efficacy of Vilaprisan in Japanese Subjects With Uterine Fibroids and Heavy Menstrual Bleeding
To evaluate the safety and efficacy of vilaprisan in Japanese subjects with uterine fibroids and heavy menstrual bleeding (HMB).
Uterine Fibroids and Heavy Menstrual Bleeding
DRUG: Vilaprisan (BAY1002670)
Incidence of treatment-emergent adverse event, Up to one year and 3 months
Number of bleeding days, Up to one year and 3 months
To evaluate the safety and efficacy of vilaprisan in Japanese subjects with uterine fibroids and heavy menstrual bleeding (HMB).